유투바이오
Financials
Valuation Metrics
유투바이오's Market Cap is ₩605B. At end of 2025 it was ₩640B. Ranked #1653 of 2,421 in KR market (top 68%), #988 of 1,640 on KOSDAQ (top 60%), #65 of 96 in Health Care Equipment & Services (top 68%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 60.46B KRW | KR#1,653/2,421 Sec#65/96 |
| Revenue | 32.14B KRW | KR#2,007/2,421 Sec#62/96 |
| Net Income | -5.72B KRW | KR—/2,421 Sec—/96 |
| Total Assets | 78.02B KRW | KR#1,947/2,421 Sec#63/96 |
| Net Assets | 60.36B KRW | KR#1,785/2,421 Sec#55/96 |
| Employees | 101 | KR#1,628/2,421 Sec#58/96 |
| Value | ||
| P/B | 1.00x | KR#1,467/2,421 Sec#39/96 |
| P/S | 1.88x | KR#1,772/2,421 Sec#49/96 |
| FCF Yield | -2.74% | KR—/2,421 Sec—/96 |
| Profitability | ||
| ROE | -9.47% | KR#1,928/2,421 Sec#66/96 |
| ROA | -7.33% | KR#2,025/2,421 Sec#71/96 |
| Op. Margin | -11.16% | KR#2,017/2,421 Sec#65/96 |
| Revenue Growth | 27.81% | KR#415/2,421 Sec#22/96 |
| Financial Health | ||
| Debt Ratio | 29.27% | KR#567/2,421 Sec#30/96 |
| Total Debt | 640.0M KRW | KR#1,989/2,421 Sec#80/96 |
| FCF | -1.65B KRW | KR#1,316/2,421 Sec#39/96 |
| Cash | 10.12B KRW | KR#1,688/2,421 Sec#54/96 |
| Current Ratio | 2.84x | KR#600/2,421 Sec#36/96 |
| Dividend | ||
| Div. Yield | 2.69% | KR#708/2,421 Sec#15/96 |
| Div. Growth | 60.00% | KR#201/2,421 Sec#11/96 |
| Performance | ||
| 1Y Return | 16.88% | KR#473/2,421 Sec#12/96 |
| 1M Return | -9.08% | KR#2,053/2,421 Sec#76/96 |
| From 52W High | -88.70% | KR#2,404/2,421 Sec#94/96 |
| 1Y MDD | -87.16% | KR#2,392/2,421 Sec#94/96 |
| Trading | ||
| Volume | 40,149 shares | KR#1,237/2,421 Sec#42/96 |
| Trading Value | 148.1M KRW | KR#1,383/2,421 Sec#58/96 |
| Foreign Own. | 2.68% | KR#1,395/2,421 Sec#50/96 |
| Per Share | ||
| EPS | -350 KRW | KR—/2,421 Sec—/96 |
| BPS | 3,699 KRW | KR#1,725/2,421 Sec#45/96 |
Company Info
Established in 2009, this company was listed on the KONEX market in 2015 and transferred to the KOSDAQ market in 2023. It operates in vitro diagnostic testing services and medical IT solutions, collecting specimens from hospitals and clinics nationwide through directly managed stores and agencies, and delivering analysis results via partner medical institutions. The company is pursuing pharmaceutical clinical services with partner medical institutions and U2Biome, an NGS-based personalized health management solution, as new growth engines. U2Bio was established in 2009 and is headquartered in Songpa-gu, Seoul Metropolitan City.